{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-22-000122","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.760951+00:00","generated_at":"2026-06-24T02:54:03.242750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Denali reports Q2 net loss $58.8M; collaboration revenue $52.5M on $40M Sanofi milestone","bullets":["Net loss $58.8M vs $60.7M year ago; cash and securities $1.16B as of June 30, 2022.","Collaboration revenue $52.5M, up from $22.9M, driven by $40M milestone from Sanofi (RIPK1) and $12M from Takeda (TREM2 CTA).","R&D expenses $92.7M (+41% YoY) due to clinical progress in ETV:IDS, LRRK2, and TV platform programs.","Phase 1 dosing started for DNL919 (ATV:TREM2) in Alzheimer’s; Phase 2b LUMA study for BIIB122 in Parkinson’s underway.","Initiated Phase 2/3 COMPASS study for DNL310 in Hunter syndrome; data presentations planned for H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-22-000122","json":"https://secwatch.observer/filing/0001714899-22-000122.json","markdown":"https://secwatch.observer/filing/0001714899-22-000122.md","text":"https://secwatch.observer/filing/0001714899-22-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/0001714899-22-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000122/dnli-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:54:03.242750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}